

| Corresponding author(s): | Chrysoula Pitsouli |
|----------------------------|--------------------|
| Last updated by author(s): | Mar 18, 2021 |

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

| Statistics | |
|--|--|
| For all statistical analys | es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. |
| n/a Confirmed | |
| ☐ ☐ The exact sam | pple size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| A statement of | on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| The statistical Only common to | test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section. |
| A description | of all covariates tested |
| A description | of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| A full descript AND variation | ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| For null hypot | hesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted exact values whenever suitable. |
| For Bayesian a | analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| For hierarchic | al and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| Estimates of e | effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |
| , | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. |
| Software and c | ode |
| Policy information abou | ut <u>availability of computer code</u> |
| Data collection | LCS (Leica); LAS X (Leica); Axiovision (Zeiss) |
| Data analysis | Photoshop 2020 (Adobe); ImageJ 1.52q (NeuronJ plugin, NIH); ICY (http://icy.bioimageanalysis.org/); Excel v.16 (Microsoft); Prism 9 (GraphPad) |
| - | om algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. |
| Data | |
| Accession codes, unA list of figures that | ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability |
| All data supporting the fi | ndings of this study are available from the corresponding authors on reasonable request. |
| | |
| Field-speci | fic reporting |
| Please select the one b | elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. |
| ✓ Life sciences | Behavioural & social sciences |

Life sciences study design

| All studies must disclose on these | points even when | the disclosure is negative. |
|------------------------------------|------------------|-----------------------------|
|------------------------------------|------------------|-----------------------------|

Sample size

Drosophila numbers are not limiting, and thus pre-determining sample size is not necessary. Sample sizes were determined empirically, based on the expected variations upon different genotypes and treatments, and the processing time required for each experiment. In each experimental condition, similar sample sizes were used to make comparisons.

Data exclusions

No data were excluded from the analyses.

Replication

All experiments were repeated 2-3 times with the same results. Representative experiments are shown in the manuscript. Key points of the study were also verified using different genotypes (e.g. Gal4 drivers with the same tissue specificity or independent RNAi lines targeting the same gene).

Randomization

The allocation of experimental organisms (flies) into groups was random. For example, from pools of animals of the same genotype, age and sex, we generated different experimental groups, which were subsequently subjected to various treatments.

Blinding

Blinding was performed for some experiments quantifying tracheal phenotypes (e.g. Fig. 1k, Fig. 7a,c). For all others, the experimenter was not blind to the fly genotypes.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | | |
|----------------------------------|-----------------------|--|
| n/a | Involved in the study | |
| | Antibodies | |

☐ ☐ Antibodies
☐ Eukaryotic cell lines

Palaeontology

Animals and other organisms

Human research participants

Clinical data

Methods

n/a Involved in the study

ChIP-seq

Flow cytometry

MRI-based neuroimaging

Details of the time line for each experiment are provided in the methods section of the paper.

Antibodies

Antibodies used

All antibodies used in the study are commercially available: rabbit-anti-pH3 (#06-570, Millipore 1:4000); rabbit anti-cleaved-Caspase-3 (#9661, Cell Signaling Technology 1:400); mouse-anti-Prospero (MR1A, DSHB 1:100); mouse anti- β -gal (Z3781, Promega 1:500); chicken-anti-GFP (A10262, Invitrogen 1:1000); rabbit anti-GFP (A11122, 1:3000; Invitrogen). Secondary antibodies against mouse, rabbit or chicken conjugated to Alexa Fluor 488 and 555 (A31572, A11039, A21206, A31570, Invitrogen) were used at 1:1000.

Validation

All antibodies used in the study were previously validated to work specifically in the Drosophila midgut: rabbit-anti-pH3, and mouse-anti-Prospero (Micchelli and Perrimon, 2006); mouse anti- β -gal, rabbit anti-cleaved-Caspase-3, chicken-anti-GFP, and rabbit anti-GFP (Apidianakis et al., 2009).

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals

The study involved the use of Drosophila melanogaster. Mature (3-5 days old) mated females were used for all experiments.

Wild animals The study did not involve wild animals.

Field-collected samples

The study did not involve samples collected from the field.

Ethics oversight The use of Drosophila does not require ethical approval.

Note that full information on the approval of the study protocol must also be provided in the manuscript.